pentamethylenetetrazol
A scientist carefully measures a dose of pentamethylenetetrazol in a laboratory.
Noun: A synthetic chemical compound used primarily in medical and research contexts as a central nervous system stimulant. Historically, it was employed to stimulate circulation and respiration, and at higher doses, to induce convulsions in certain types of shock therapy.
This is a highly technical, scientific term. It is used almost exclusively in medical, pharmacological, and historical contexts. * The study examined the effects of pentamethylenetetrazol on seizure thresholds in the animal model. * In mid-20th century psychiatry, pentamethylenetetrazol was sometimes administered to induce therapeutic convulsions.
- Research Context: The compound is frequently used in laboratory research as a convulsant agent to study epilepsy, anticonvulsant drugs, and neuronal excitability.
- The researchers injected pentamethylenetetrazol to trigger a controlled seizure for their epilepsy study.
- Metrazol: A former trademark name for pentamethylenetetrazol, now often used generically to refer to the same substance. This is the most common synonym in historical medical literature.
- The therapy, sometimes called Metrazol shock therapy, is no longer in use.
- Metrazol (trademark/generic name)
- PTZ (common research abbreviation)
- Cardiazol (another historical brand name)
- Convulsant stimulant (descriptive term for its pharmacological class and effect)
This word refers specifically to a single, defined chemical compound. Its meanings are not figurative but are strictly tied to its pharmacological properties: 1. A circulatory/respiratory stimulant (at lower doses). 2. A convulsant agent (at higher doses), which was its primary use in historical psychiatric "shock" therapies and remains its key use in scientific research.
A scientist carefully measures a dose of pentamethylenetetrazol in a laboratory.
- a drug used as a circulatory and respiratory stimulant; larger doses cause convulsions in shock therapy; Metrazol is a trademark